MARKET WIREMoomoo • 20h ago
Jasper Therapeutics(JSPR) Stock Options Chain | Quotes & NewsMoomoo report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
Why JSPR Stock dropped -2.35% Today — RQD Quant Desk Flash
$0.51 -2.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.51
Jasper Therapeutics Inc. (JSPR) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $17.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on JSPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.51 (-2.35% 1D, market cap $17.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, JSPR ranks #577 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does JSPR compare to PLUR and SCLX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for JSPR?
▼
Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $234.9M in revenue (+10.0% YoY), -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.51 (-0.61%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JSPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY JSPR SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.50+0% Next Q
28
Q2 (-2Q)Grade E$0.50+4% Next Q
31
Q3 (-1Q)Grade E$0.52-1.9% Next Q
33
CurrentGrade D-$0.51-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a JSPR Turnaround Squeeze
While JSPR currently carries a cautious 36/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.59) and Max Pain ($0.54) forces dealer call-delta covering toward $2.54.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $JSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why JSPR Stock dropped -2.35% Today — RQD Quant Desk Flash
Jasper Therapeutics Inc. (JSPR) dropped -2.35% to $0.51, trading at 9% of its 52-week range ($0.31 – $2.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($0.31 – $2.42) with RSI-14 at 44.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.51 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live JSPR Headlines & Catalysts
MARKET WIREStock Titan • 23h ago
Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split.Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA NephropathyYahoo Finance report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Jasper Therapeutics, Inc. Estimates – NASDAQ:JSPRTradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsGlobeNewswire report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Jasper Therapeutics completes IgAN cohort enrollment; interim data due by year-end 2026TradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 millionad-hoc-news.de report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026.Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 19d ago
William Blair Reinstates Outperform on Jasper TherapeuticsWilliam Blair analyst Matt Phipps reinstates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JSPR)
- ✓Walkthrough of JSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.48%⚡ TESTING RESISTANCE
2026-11-03O $0.53H $0.53L $0.51C $0.51VOL 396.1K
RES: $0.55SUP: $0.44SMA50: $0.59SMA200: $0.84
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
JSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on JSPR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for JSPR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JSPR)
Health Care Rank #577 of 1016
⚔️ PLUR vs JSPR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (JSPR vs. PLUR, SCLX, DYAI, ABOS)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Jasper Therapeutics Inc. (JSPR) ranks #577 by composite RQD confidence (36/100, grade D-) and #839 by equity capitalization ($17.3M). Within this direct 5-issuer industry benchmark cohort, JSPR leads on earnings valuation at N/A trailing P/E, while JSPR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JSPR at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| JSPR
ACTIVE
Jasper Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -2.35% | $17.3M | Benchmark Subject |
| PLUR Pluri Inc. | E | 34/100 | — | 49.0% | -35.0% | -3.23% | $16.7M | /plur-vs-jspr → |
| SCLX Scilex Holding Company | D- | 40/100 | — | 96.0% | -35.0% | +1.08% | $15.7M | /sclx-vs-jspr → |
| DYAI Dyadic International Inc. | E | 31/100 | — | 24.9% | -35.0% | -1.10% | $15.2M | /dyai-vs-jspr → |
| ABOS Acumen Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | +14.09% | $15.2M | /abos-vs-jspr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001788028In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported GAAP revenue of $234.9M (+10.0% vs. FY2024 revenue of $213.5M , and +21.8% cumulative change since FY2023) , GAAP net income of -$76, operating cash flow of -$77.2M, and free cash flow of -$77.2M (-23.3% YoY). On the balance sheet, JSPR closed FY2025 with $35.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $234.9M | -$76 | -$77.2M | -$77.2M | $35.8M | — |
| FY2024 (FY) | 2024-12-31 | $213.5M | -$71.3M | -$62.6M | -$62.6M | $79.9M | — |
| FY2023 (FY) | 2023-12-31 | $192.8M | -$64.5M | -$52.1M | -$52.1M | — | — |
3. JSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.51 (-2.35% 1D, market cap $17.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, JSPR ranks #577 in composite RQD confidence.
How does JSPR compare to PLUR and SCLX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for JSPR?
Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $234.9M in revenue (+10.0% YoY), -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is JSPR trading relative to its 50-day, 200-day, and 52-week technical levels?
JSPR last traded at $0.51 (-2.35% on volume of 452,333 shares), positioning the stock -13.56% below its 50-day simple moving average ($0.59) and -39.29% below its 200-day simple moving average ($0.84). Across its 52-week range of $0.31 to $2.42, JSPR sits at the 9.5% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.57).
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ SEC XBRL & RQD VERIFIED
JSPR — Jasper Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Jasper Therapeutics Inc. (JSPR) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.51 (-2.35% 1D, market capitalization $17.3M).
- Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Jasper Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.0B on a rounded basis, consistent with the $17.7M figure in market data. Per the news wire, the company's clinical program includes vensobafusp alfa (KP104) in IgA Nephropathy, with a Phase 2 renal basket study cohort reported as having completed enrollment.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported $234.9M in annual revenue (up from $213.5M in FY2024, +10.0% YoY) and -$76 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($192.8M revenue, -$64.5M net income) through FY2025, JSPR scaled operating cash flow to -$77.2M and free cash flow to -$77.2M, backed by $35.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.31 – $2.42 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), JSPR carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can JSPR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $234.9M and free cash flow of -$77.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is JSPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
JSPR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Jasper Therapeutics Inc. (JSPR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Moomoo • 20h ago
Jasper Therapeutics(JSPR) Stock Options Chain | Quotes & News Moomoo report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Yahoo Finance report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Jasper Therapeutics, Inc. Estimates – NASDAQ:JSPR TradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants GlobeNewswire report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Jasper Therapeutics completes IgAN cohort enrollment; interim data due by year-end 2026 TradingView report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million ad-hoc-news.de report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. Stock Titan report covering Jasper Therapeutics Inc. (JSPR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
JSPR Bull vs. Bear Conversation Board — What's Your Call at $0.51?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JSPR 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $0.64 (+23.1%)
📌 Pinned Debate Phase 2 IgAN cohort enrollment completed with interim data due by year-end 2026, a potential near-term clinical catalyst.
Here is why I am bullish on JSPR here at $0.52: Phase 2 IgAN cohort enrollment completed with interim data due by year-end 2026, a potential near-term clinical catalyst.. Compare JSPR's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.49 are getting bought.
EarningsSniper 🐂 BULL
@RiskArb_Desk Shorting a 9/20 institutional whale-flow stock at $0.52 is dangerous when funds are rotating into Health Care.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $0.39 (-25.0%)
Spot @ $0.52 Operating losses widened to -$83.9M with FCF of -$77.2M against reported cash of $28.7M and a 0% FCF yield.
Sitting on the sidelines or leaning short JSPR above $0.52. Operating losses widened to -$83.9M with FCF of -$77.2M against reported cash of $28.7M and a 0% FCF yield.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.42.